stockportfolio.pro
IRADIMED CORPORATION (IRMD)
Healthcare · Medical Devices · NasdaqGM
IRADIMED CORPORATION revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.50M | $23.08M | $30.44M | $38.52M | $31.72M | $41.81M | $53.30M | $65.56M | $73.24M | $83.81M |
| Gross profit | $26.34M | $17.51M | $23.23M | $29.70M | $23.57M | $32.05M | $41.28M | $50.16M | $56.35M | $64.32M |
| Net income | $7.21M | $499,764 | $6.30M | $9.63M | $1.37M | $9.33M | $12.83M | $17.19M | $19.23M | $22.48M |
| Net margin | 22.2% | 2.2% | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
Source: IRADIMED CORPORATION SEC filings (10-K). 13 years of history available in the interactive view.
What growth is priced into IRMD stock?
At today's market cap of $1.22B, IRADIMED CORPORATION is priced for free-cash-flow growth of about 25.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $16.53M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 25.2%/yr over the last five fiscal years and revenue 21.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 13 years of IRADIMED CORPORATION financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IRMD in your portfolio →
IRADIMED CORPORATION financial history by metric
About IRADIMED CORPORATION
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
IRADIMED CORPORATION — frequently asked questions
What is IRADIMED CORPORATION's revenue?
IRADIMED CORPORATION (IRMD) reported revenue of $83.81M for fiscal year 2025, up 14.4% from the prior year, according to its SEC filings.
Is IRADIMED CORPORATION profitable?
Yes. IRMD earned net income of $22.48M in fiscal 2025, a net margin of 26.8%.
What is IRMD's P/E ratio?
IRADIMED CORPORATION trades at a price-to-earnings ratio of about 52.3 based on the latest data in our nightly-refreshed cache.
How fast is IRADIMED CORPORATION growing?
IRMD's revenue grew at roughly 21.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does IRADIMED CORPORATION have?
As of fiscal year 2025, IRMD carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is IRADIMED CORPORATION's gross margin?
IRMD's gross margin was 76.7% in fiscal 2025 — gross profit of $64.32M on revenue of $83.81M.
What is IRADIMED CORPORATION's market cap?
IRADIMED CORPORATION (IRMD) has a market capitalization of about $1.22B, based on the latest data in our nightly-refreshed cache.
When does IRADIMED CORPORATION's fiscal year end?
IRMD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into IRMD stock?
At today's market cap of $1.22B, IRADIMED CORPORATION is priced for free-cash-flow growth of about 25.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $16.53M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 25.2%/yr over the last five fiscal years and revenue 21.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from IRADIMED CORPORATION's official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.